Clin2
NCT07088354Possibly a fitRecruiting

AI model predicts treatment response in esophageal cancer

Esophageal Squamous Cell CarcinomaNeoadjuvant ImmunochemotherapyPathological Complete ResponseDeep Learning

Part of Cancer, Digestive system clinical trials.

This trial tests whether an artificial intelligence (AI) model can accurately predict if esophageal cancer will completely disappear after chemotherapy combined with immunotherapy before surgery. If successful, it could help doctors decide the best treatment plan for patients.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
300 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must have a confirmed diagnosis of esophageal squamous cell carcinoma (a specific type of esophageal cancer).
  • You must have received at least one round of chemotherapy combined with immunotherapy before surgery (neoadjuvant treatment).
  • You must have had a CT scan with contrast dye before starting neoadjuvant treatment.
  • You must have had a CT scan with contrast dye after finishing neoadjuvant treatment and before surgery.
  • You cannot have had any other cancer or received any other anti-cancer treatments before or during this neoadjuvant therapy.
  • Your medical records must be complete, and your CT images must be of good quality.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07354295Recruiting
Using AI to predict treatment response in esophageal cancer

This trial uses a combination of imaging and clinical data to see if a computer model can predict how well your treatment will work. It aims to help doctors better understand your cancer risk and choose the best treatment plan for you.

Wuhan, Other (Non U.s.)
NCT07287904Not yet recruiting
AI predicts targeted therapy success for EGFR-mutant lung cancer

This trial uses artificial intelligence (AI) to analyze your medical images, genetic tests, and pathology reports to see how well targeted therapy (EGFR-TKI) works after lung cancer surgery. It may help doctors better predict treatment outcomes.

Wuhan, Hubei
NCT07063901Recruiting
Predicting esophageal cancer treatment response with AI and imaging

This trial uses artificial intelligence to analyze CT scans and predict how well esophageal cancer responds to chemotherapy combined with immunotherapy before surgery. The goal is to help doctors personalize treatment for better outcomes.

Changsha, Hunan
NCT07203690Not yet recruiting
AI imaging for esophageal cancer treatment decisions

This trial is testing an AI system that uses MRI scans and tissue samples to help doctors choose the best treatment for esophageal cancer. It's only for people who haven't had any cancer treatment yet.

NCT07757022Not yet recruiting
AI-guided treatment planning for esophageal cancer

This trial uses artificial intelligence to create a digital twin of your cancer and simulate how it might respond to different treatments. The goal is to find the best treatment plan for you before you start therapy.

NCT07401199Recruiting
AI predicts immunotherapy response in advanced stomach cancer

This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.

Fuyang, Anhui

Hear when a new Esophageal Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.